Abstract
Carriage of medicaments assigned in the forms of conventional dosage is restricted to the eye; moreover, favorable drug concentrations in the destination tissues are not kept up for an extended time spread given that the eyes are escorted via an inimitable anatomy, physiology and biochemistry. The clear- cut aim of designing a therapeutic system is to attain a desirable concentration of a drug at the active site for the relevant duration. A successful design of a drug- delivery system, therefore, desires an integrated knowledge of the drug molecule and the restrictions offered by the ocular route of administration. In last decade, with the emergence of miscellaneous powerful and multifaceted medicinal substitutes, the assortment of traditional ophthalmic preparations has progressively developed; drawing out considerably apart from ordinary solutions, suspensions and ointments, presently comprises a diversity of drug administration formats. Present communication echoes miscellaneous barriers and successive blossoms in the field of ocular therapeutics.
References
Lang J C, “Ocular drug delivery: conventional ocular formulations”, Adv Drug Delivery Revs, 1995, 16, 39–43.
Satish K S, Bandyopadhya, Paramita. “Pharmacia Corporation. Ophthalmic formulation with novel gum composition”, 2006, US 7128928.
Emami J, “In vitro - In vivo Correlation: From Theory to Applications”, Journal of pharmacy & pharmaceutical sciences, 2006, 9(2), 169-189.
Mishima S, Gasset A, Klyce SD, Baum JL, “Determination of tear volume and tear flow”, Invest Ophthalmol, 1966, 5, 264–276.
Peyman GA, Ganiban GJ, “Delivery systems for intraocular routes”, Advanced DrugDelivery Reviews, 1995, 16(1), 107-123.
Hull DS, Green K, Boyd M, Wynn HR, “Corneal endothelium bicarbonate transport and the effect of carbonic anhydrase inhibitors on endothelial permeability and fluxes and corneal thickness”, Investigative Ophthalmology and Visual Science, 1977, 16 (10), 883-892.
Wissing SA, Kayser O, Muller RH, “Solid lipid nanoparticles for parenteral drug delivery”, Advanced Drug Delivery Reviews, 2004, 56(9), 1257-1272.
Mitra AK, “Role of transporters in ocular drug delivery system”, Pharm Res, 2009, 26, 1192– 1196.
Kaur IP, Garg A, Singla AK, Aggarwal D, “Vesicular systems in ocular drug delivery: an overview”, Int J Pharm, 2004, 269, 1–14.
Macha S, Mitra AK, “Ophthalmic drug delivery systems” second edition revised and expanded, Informa Healthcare, 2003, Chapter 1, Overview of Ocular Drug Delivery, 1-3.
Mundada AS, Avari JG, Mehta SP, Pandit SS, Patil AT, “Recent advances in ophthalmic drug delivery system”, Pharm Rev, 2008, 6(1), 24-26.
Records RE, “The tear film. In Duane’s ophthalmology on CD-ROM, Foundations of Clinical Ophthalmology”, vol 2, 2002, eds W Tasman and EA Jaeger Philadelphia, Lippincott Williams & Wilkins, chap 3.
Norn MS, “Tear secretion in normal eyes. Estimated by a new method: The lacrimal streak dilution test”, Acta Ophthalmol (Copenh), 1965, 43,567.
Patton TF, Robinson JR, “Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes”, J Pharm Sci, 1976, 65, 1295.
Maurice D, “The effect of the low blink rate in rabbits on topical drug penetration”, J Ocul Pharmacol Ther, 1995, 11:297.
Van SL, Ludwig A, “The influence of penetration enhancers on the volume instilled of eye drops” Eur J Pharm Biopharm, 1998, 45, 189-198.
Chrai SS, Patton TF, Mehta A, Robinson JR, “Lacrimal and instilled fluid dynamics in rabbit eyes”, J Pharm Sci, 1973, 62, 1112–1121.
Zaki I, Fitzgerald P, Hardy JG, “A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man”, J Pharm Pharmacol, 1986, 38, 463-466.
Ahmed I, Patton TF, “Disposition of timolol and inulin in the rabbit eye following corneal versus noncorneal absorption”, Int J Pharm, 1987, 38, 9– 21.
Watsky MA, Jablonski MM, Edelhauser HF, “Comparison of conjunctiva and corneal surface areas in rabbits and human”, Curr Eye Res, 1988, 7, 483–486.
Wang W, Sasaki H, Chien DS, Lee VHL, “Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration”, Curr Eye Res, 199110, 571–579.
Lee VHL, Robinson JR, “Topical ocular drug delivery: recent developments and future challenges”, J Ocul Pharmacol, 1986, 2, 67.
Desai SD, Blanchard J, “Ocular drug formulation and delivery, In: Swarbick J, Boylan, JC (Ed), Encyclopedia of Pharmaceutical Technology, vol 11, Marcel Dekker, New York, 1994, 43–75.
Sukhbir S, Chrai, Joseph R Robinson, “Binding of sulfisoxazole to protein fractions of tears”, Journal of Pharmaceutical Sciences, 1976, 65(3), 437–439.
Thomas J, Mikkelson, Sukhbir S, Chrai, Joseph R Robinson, “Altered bioavailability of drugs in the eye due to drug-protein interaction”, Journal of Pharmaceutical Sciences, 1973, 62 (10),1648– 1653.
Larsson BS, “Interaction between chemicals and melanin”, Pigment Cell Res, 1993, 6(3), 127–33.
Leblanc B, Jezequel S, Davies T, Hanton G, Taradach C, “Binding of drugs to eye melanin is not predictive of ocular toxicity”, Regul Toxicol Pharmacol, 1998, 28(2), 124–32.
Pitkanen L, Ranta VP, Moilanen H, Urtti A, “Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium”, Pharm Res, 2007, 24(11),
–70.
Schoenwald RD, Tandon V, Wurster DE, Barfknecht CF, “Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino- 4-methyl-delta2–1, 3, 4,-thiadiazolin e-2- sulfonamide”, Eur J Pharm Biopharm, 1998, 46(1), 39–50.
Salminen L, Imre G, Huupponen R, “The effect of ocular pigmentation on intraocular pressure response to timolol”, Acta Ophthalmol Suppl, 1985, 173, 15–8.
Hui HW, Robinson JR, “Ocular Delivery of Progesterone using a bioadhesive polymer”, Int J Pharma, 1985, 26, 203.
Swanson AA, Jeter DJ, Tucker P, “Ophthalmic vehicles II. Comparison of ointment and polyvinyl alcohol 1.4%”, Ophthalmologica, 1970, 160, 265- 70.
Krishnamoorthy R, Mitra A K, “Mucoadhesive polymers in ocular drug delivery” Ophthalmic Drug Delivery systems, (Ed. A K Mitra), M Dekker, Inc, New York, 1993, 199–222.
Ludwig A, “The use of mucoadhesive polymers in ocular drug delivery”, Adv Drug Del Rev, 2005, 571, 595-1639.
Lee JW, Park JH, Robinson JR, “Bioadhesive based dosage forms – the next generation”, J Pharm Sci, 2000, 89, 850-866.
Rojanasakul Y, Paddock SW and Robinson JR, “Confocal laser scanning microscopic examination of transport pathways and barriers of some peptides across the cornea”, Int J Pharm, 1990, 61,163.
Keistea JC, Cooper ER, Missel PJ, Long JC, Hager DF, “Limits on optimizing ocular drug delivery” J Pharm Sci, 1991, (80) 50.
Hill JM, Callaghan RJ O’, Hobden JA, Kaufman HE, “Corneal collagen shields for Ocular delivery”, In: AK Mitra, ed Ophthalmic Drug Delivery Systems, New York, Marcel Dekker, 1993, 261–273.
Kim SW, Bae YH, Okano T, “Hydrogel: swelling, drug loading and release”, Pharm Res , 1992, 9, 283-290.
Burrows J, Tslbouklls J, Smart J, “Drug delivery to the eye”, Biomaterials and drug delivery group Pharmaventure Ltd. ,The drug delivery companies report, spring 2002.
Middleton DL, Robinson JR, “Design and evaluation of an ocular bioadhesive delivery system”, STP Pharmaceutical Science, 1991, 1, 200-6.
Miller SC, Donovan MD, “Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits”, Int J Pharm, 1982, 12, 147.
Michael H, Mostafa H, Mehdi J., Taravat G, “Draize Rabbit eye test compatibility with eye irritation
threshold in humans: A quantitative structural-activity relationship analysis”, Toxicological Sci, 2003, 2(76), 384-391.
Saettone M F, “Solid polymeric inserts/disks as drug delivery devices”, Biopharmaceutics of Ocular Drug Delivery, (Ed. P Edman), CRC Press, Boca Raton, 1993, 61–80.
Neefe CW, “Contact lens for ocular drug delivery” US Patent. 1974, 3, 786–812.
Korsmeyer RW, Peppas NA, “Macromolecular and modeling aspects of swelling-controlled systems” In: Roseman TJ, Mansdorf SZ, editors. Controlled Release Delivery Systems, New York, Marcel Dekker, 1983.
Darougar S, “Patent literature review of ocular inserts” US Patent, 1999, 6, 264–971.
lnduPal K, Meenakshi K, “Ocular preparations: the formulation approach” Drug Develop Ind Pharm Sci, 2002, 473.
Kurz D, Ciulla TA, “Novel approaches for retinal drug delivery”, Ophthalmol Clin North Am, 2002, 15, 405-410.
Megaw JM, Tukei Y, Lerman S, “Lectin mediated binding of liposomes to ocular lens”, Exp Eye Res, 32, 1981, 395-405.
Shek PN, Barber RA “Liposomes are effective carrier for the ocular delivery of propylactics”, Biochem Biophysic Acta, 1987, 902, 229-236.
Law SL, Huang KJ, Chiang CH, “Acyclovir-containing liposomes for potential ocular delivery –corneal penetration and absorption”, J Control.Release, 2000, 63, 135-140.
Carafa M, Santucci E, Alhaique F, Coviello T, Murtas E, Riccieri FM, Lucania G, Torrisi MR, “Preparation and properties of new unilamellar non-ionic surfactant vesicles” Int J Pharm, 1998, 160, 51–59.
Baillie AJ, Florence AT, “The preparation and properties of niosomes - non ionic surfactant vesicles”, J Pharm Pharmacol, 1985, 37, 863-868.
Carafa M, Santucci E, Lucania G, “Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies”, Int J Pharm, 2002, 231, 21–32.
Vora B, Khopade AJ, Jain NK, “Proniosome based transdermal delivery of levonorgestrel for effective contraception”, J Control Rel, 1998, 54, 149–165.
Friedberg ML, Pleyer U, Mondino BJ, “Device drug delivery to the eye. Collagen shields, iontophoresis, and pumps”, Ophthalmology, 1991, 98, 725–732.
Menqi SA, Desh Pande SG (Eds.), In:N.K.Jain, “Controlled and Novel drug delivery systems”, CBS publishers, New delhi, 2004, 82-96.
Kaufman HE, Steinemann TL, Lehman E, Thompson HW, Varnell ED, Jacob-Labarre T, “Collagen-based drug delivery and artificial tears”, Journal of Ocular Pharmaceutical. 1994, 10, 17-27.
Gilger BC, Salmon JH, Wikkie DA, “A novel bioerodible deep scleral lamellar cyclosporineimplant for uveitis”, Invest Ophthalmol Visual Sci, 2006, 47, 2596-2605.
Sallmann V L, “Iontophoretic introduction of atropine and scopolamine into the rabbit eye”, Arch Ophthalmol, 1943, 29, 711-719.
Hughes L, Maurice DM, “A fresh look at iontophoresis”, Arch Ophthalmol, 1984, 102 (12), 1825-1829.
Jones RF, Maurice DM, “New methods of measuring the rate of aqueous flow in man with fluorescein” Exp Eye Res, 1966, 5(3), 208-220.
Rootman DS, Jantzen JA, Gonzalez JR, Fischer MJ, Beuerman R, Hill JM, “ Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit”, Ophthalmologic Visual Science, 1988, 29, 1397-401.
Kreuter J, “Nanoparticles. In: Colloidal Drug Delivery Systems”, New York, Marcel Dekker, 1994, Chapter 5.
Barratt GM, “Therapeutic applications of colloidal drug carriers” Pharm Sci Technol, 2000, 3, 163- 171.
Couvreur P, Dubernet C, Puisieux F, “Controlled drug delivery with nanoparticles: current possibilities and future trends”, Eur J Pharm Biopharm, 1995, 41, 2-13.
Antoine BR, Francine BC, David B, Robert G, Florence D, “Polymeric nanoparticles for drug delivery to the posterior segment of the eye”, CHIMIA Intl J Chem, 2000, 559 (6), 344-347.
Ambade AV, Savariar EN, Thayumanavan S, “Dendrimeric micelles for controlled drug release and targeted delivery”, Mol Pharmacol, 2005, 2, 264-272.
Barbu E, Verestiuc L, Nevell T G, Tsibouklis J, “Polymeric materials for ophthalmic drug delivery: trends and perpectives”, J Material Chem, 2006, 16, 3439-3443.
Mainardes RM, Urban MCC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, Gremiao MPD, “Colloidal Carriers for Ophthalmic. Drug Delivery”, Curr Drug Targets, 2005, 6, 363-371.
Alonso MJ, “Nanomedecine for overcoming biological barriers”, Biomed Pharmacother, 2004, 58, 168-172.
Kumar S, Haglund BO, Himmelstein KJ, “In situ- forming gels for ophthalmic drug delivery”, J Ocul Pharmcol, 1994, 10(1), 47-56.
Newkome GR, Moorefield C, Vögtle F, “Dendrimers and Dendrons: Concepts, Syntheses, Perspectives”, VCH Weinheim Germany, 2001.
Shakti KS, Lohiya GK, Limburkar PP, Dharbale NB, Mourya VK, “Dendrimer a versatile polymer in drug delivery”, Asian J of Pharm, 2009, 3, 178- 182.
Tolia GT, Choi HH, Ahsan F, “The role of dendrimers in drug delivery”, Pharmaceut Tech, 2008, 32, 88– 98
Vandamme TF and Brobeck L (2005). Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. Journal of Controlled Release. 102: 23–38.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array